Shenzhen Glion Biotechnology

Shenzhen Glion Biotechnology is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the development of next-generation cell therapies for cancer. The company focuses on chimeric antigen receptor T-cell (CAR-T) and TCR-T technologies, with a particular emphasis on overcoming the challenges of treating solid tumors such as hepatocellular carcinoma. Its lead program, GL-001, is an autologous CAR-T therapy targeting Glypican-3 that is currently undergoing clinical evaluation. Glion utilizes proprietary genetic engineering techniques to create "armored" immune cells designed to resist the immunosuppressive tumor microenvironment. The company maintains integrated research, development, and manufacturing facilities to support its pipeline of multi-target and precision cell therapies.